To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. If you experience any issues with your products or services, please contact ATCC Customer Service at sales@atcc.org. For Technical questions please contact tech@atcc.org. Thank you.
X

FAQ's

FAQ Home

Find Answers

Validation

How is the KRASG13D mutant-A375 Isogenic cells (ATCC® CRL-1619IG-1 ™) validated?

This line has been tested in parallel with the A-375 [A375] (ATCC® CRL-1619 ™) parental line at the genomic, transcript and cellular levels as well as assayed for the desired phenotypic functional activity resembling the intended genotypic G13D heterozygous knock-in mutation.  We observed significant levels of drug resistance to both BRAF-specific inhibitors, Dabrafenib and Vemurafenib treatment. 

Date Created09/28/2017 03:42 PM
Date Updated09/28/2017 03:43 PM

Most Popular Answers

  1. Huh7 cell line
  2. ATCC HUVEC lines
  3. Passage number vs. population doubling level (PDL)
  4. Converting TCID[50] to plaque forming units (PFU)
  5. U-373 MG (ATCC® HTB-17)